KCM
STIM icon

Kennedy Capital Management’s Neuronetics STIM Stock Holding History

Kennedy Capital Management’s Portfolio STIM Stock Details STIM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-47,827
Closed -$215K – 725
2019
Q4 		$215K Sell
47,827
-1,046
-2% -$6.5K 0.01% 679
2019
Q3 		$406K Buy
+48,873
New +$534K 0.01% 647

Other funds holding STIM

IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Kennedy Capital Management's STIM Position: Q1 2020 in Review

Kennedy Capital Management sold out of Neuronetics (STIM) in Q1 2020, closing a stake of 47,827 shares — an estimated $215K sold.

Kennedy Capital Management first reported a position in STIM in Q3 2019 and held it in 2 quarters. The position peaked at $406K in Q3 2019. 59 funds tracked by Wall St. Rank hold STIM as of Q1 2020.

  • Kennedy Capital Management reported no remaining Neuronetics position as of Q1 2020 after selling out during the quarter.
  • Kennedy Capital Management sold 47,827 Neuronetics shares in Q1 2020, an estimated $215K.
  • Kennedy Capital Management first reported a position in Neuronetics in Q3 2019 and held it in 2 quarters.
  • Kennedy Capital Management's Neuronetics position peaked at $406K in Q3 2019.
  • 59 funds tracked by Wall St. Rank held Neuronetics as of Q1 2020.

Based on Kennedy Capital Management's 13F filing for Q1 2020, filed 15 May 2020.